Most families afflicted by cancer have felt the tragic burden of dealing with the toxic effects of therapy. The U. S. government has recognized the issue and has made the elimination of side effects one of 10 national priorities as part of the recent bipartisan U.S. Cancer Moonshot Panel Report. The report said:
"Reduction in the deleterious symptoms of cancer and its treatment will encourage patients to continue with and benefit from recommended therapy and clinical trials, maintain optimal well-being, and stay engaged in family and societal roles. Furthermore, reduction in moderate-to-severe symptoms will lead to marked decrease in cancer care costs related to emergency department visits, urgent care, and unplanned hospitalizations and readmissions."
Congress passed the 21st Century Cures Act in December 2016 authorizing $1.8 billion in funding for the Cancer Moonshot over 7 years. An initial $300 million has been appropriated in fiscal year (FY) 2017 to fund Moonshot initiatives.
Tosk is at the forefront of achieving the goals of the Moonshot, which is being led by the National Cancer Institute. Tosk’s first drug recently entered human trials in cancer patients. A second drug is in the final stages of preclinical development. Both drugs have benefitted from federal and state research grants. Tosk’s team is poised to transform treatment for the benefit of patients everywhere.